# Krystal Biotech share price today (Krystal Biotech, Inc., KRYS)

> Krystal Biotech, Inc.'s earnings have grown faster than its share price. Earnings per share grew +128.0% in a year while the price moved +51.7%. KRYS · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/krys

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: $300.25 (+51.7% in a year)
- P/E: 40.8× (lower than 51% of the last 2.3 years)
- Revenue (Jun 2026): $119 M (+24.1% on a year ago)
- Profit (Jun 2026): $54.8 M (+42.9% on a year ago)
- Operating margin: 49.0% (+8.0 points on a year ago)
- ROE: 17%, FY25
- ROIC: 37.5%, against a 7.8% cost of capital: +29.7 points

The main question: yearly earnings per share moved +128.0% while the share price moved +51.7%. ## What is the Krystal Biotech share price today? Krystal Biotech, Inc.'s share price was $300.25 at the close on 5 November 2026. It has been moving sideways for 1 week. That is 2.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $198 and $375, and at that close it sat 58% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. Over the last 9.1 years the share price moved +2,885% while the S&P 500 moved +194%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Krystal Biotech pay? Krystal Biotech, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Krystal Biotech on? Krystal Biotech is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Krystal Biotech profitable? Krystal Biotech, Inc. earned $54.8 M of net profit in the Jun 2026 quarter, +42.9% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY25 profit was $205 M. Over 2 years profit has grown 332.9% a year on average. That is 45.9% of the quarter's revenue. The same quarter a year earlier earned $38.3 M. For the full year, FY25 profit was $205 M (+129.7% on the year before). Why profit moved: revenue changed +24.1% on a year earlier and the margin moved +8.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +76.1% and revenue +22.5%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Krystal Biotech make, and is it growing? Krystal Biotech, Inc. reported $119 M of revenue in the Jun 2026 quarter, +24.1% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 2 years it has grown 177.0% a year on average. The last full year, FY25, came in at $389 M. The last four reported quarters add to $440 M. FY25 revenue was $389 M, +33.9% on the year before. Recent pace: the last four quarters grew +22.5% on average, against 177.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +22.6%, against +62.8% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +64.6%, against +51.0% a year (accelerating). ## How much of every $100 of sales does Krystal Biotech keep? Krystal Biotech, Inc.'s operating margin was 49.0% in the Jun 2026 quarter, 8.0 percentage points higher than the same quarter a year ago. Across 3 years it has been between −191.6% and 41.5%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +8.0 percentage points on the year while gross margin changed +2.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Krystal Biotech's profit turning into cash? Over the last 3 years, 77% of Krystal Biotech, Inc.'s reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $201 M of operating cash against $205 M of profit. After $12.0 M of spending on assets, $189 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Krystal Biotech's cash go? Krystal Biotech, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $28.0 M on assets over the last 3 years. Averaged over those years that is 2.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $28.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Krystal Biotech's P/E ratio, and how does it compare with its own history? Krystal Biotech, Inc.'s P/E is 40.8×, in the middle of its own history: higher than 49% of past readings. Its usual P/E (the middle reading) is 40.9×, over 2.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +128.0% while the price moved +51.7%. Earnings did better than the price, which pulled the multiple down within its own range. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Krystal Biotech business getting better or worse? Krystal Biotech, Inc.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 16.3%; each line tells part of the story. This is based on 8 quarters of 3 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Krystal Biotech earn on its capital? Krystal Biotech, Inc. earned a ROE of 17% in FY25. That is up from a low of 1% in FY23. Its return on capital used (ROIC) is 29.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 52.6% net margin and 0.29× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 52.6% net margin × 0.29× asset turnover × 1.09× leverage (assets divided by equity) ≈ 16.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 37.5% − 7.8% = +29.7 percentage points. The 7.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 37.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 42.6%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Krystal Biotech have too much debt? Krystal Biotech, Inc. has total debt of $8.9 M against shareholder equity of $1.4 B as of Jun 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.01 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Krystal Biotech shareholding pattern? 12.4% of Krystal Biotech, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 9.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Krystal Biotech from balance-sheet trouble? For Krystal Biotech, Inc., the Z-score is 34.47. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 34.47 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Krystal Biotech rank in its industry? 55.0 out of 100, rank 10 of 30 in Biotechnology, with 81% of the evidence available. Krystal Biotech, Inc. scores 55.0 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 10. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 22.4 + 16.1 + 12.4 + 4.1 = 55. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Krystal Biotech compared with? Krystal Biotech ranks 10 of 30 Biotechnology companies on the 4-Factor Sector Score, with 55.0 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. Krystal Biotech, Inc. this page KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to Krystal Biotech in size? Krystal Biotech is the 26th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Madrigal Pharmaceuticals, Inc., Spyre Therapeutics, Inc. and Crinetics Pharmaceuticals, Inc. Just below it: Protagonist Therapeutics, Inc., ImmunityBio, Inc. and TG Therapeutics, Inc. ### Biotechnology companies close in size

1. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) $9.3 billion
2. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) $9.2 billion
3. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) $9 billion
4. Krystal Biotech, Inc. $8.9 billion
5. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) $8.8 billion
6. [ImmunityBio, Inc.](https://www.sectoralpha.in/us/stocks/ibrx) $8.5 billion
7. [TG Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tgtx) $8.2 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Core & Main, Inc.](https://www.sectoralpha.in/us/stocks/cnm) $9.3 billion · Industrial Distribution
2. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) $9.3 billion · Biotechnology
3. Krystal Biotech, Inc. $9.2 billion
4. [Viasat, Inc.](https://www.sectoralpha.in/us/stocks/vsat) $9.2 billion · Communication Equipment
5. [Brinker International, Inc.](https://www.sectoralpha.in/us/stocks/eat) $9.2 billion · Restaurants

## What else do people ask about Krystal Biotech? ### What were Krystal Biotech's latest quarterly results? Krystal Biotech, Inc. reported revenue of $119 M and net profit of $54.8 M for the Jun 2026 quarter. Revenue rose 24.1% and profit rose 42.9% compared with a year earlier. Earnings per share were $1.79. The operating margin was 49.0%, 8.0 percentage points higher than a year earlier (as of 5 November 2026). ### What is Krystal Biotech's market cap? Krystal Biotech, Inc.'s market capitalisation is $8.9 B at a stock price of $300.25. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Krystal Biotech performing? Krystal Biotech, Inc.'s share price has been moving sideways for 1 weeks. In its latest quarter, revenue rose 24.1% and profit rose 42.9% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running (as of 5 November 2026). ### Will Krystal Biotech's stock price go up? This page does not forecast Krystal Biotech, Inc.'s stock price. What it shows instead: the stock price is $300.25, and it has been moving sideways for 1 weeks. Its P/E of 40.8× is higher than 49% of its own last 2 years (as of 5 November 2026). ### Where is Krystal Biotech in its business cycle? Krystal Biotech, Inc.'s FY25 operating margin was 41.5%, against a 3-year range of −191.6% to 41.5%: the middle of its own range, neither a peak nor a low. The latest quarter was 49.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Krystal Biotech story? The main question: yearly earnings per share moved +128.0% while the share price moved +51.7%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Krystal Biotech a stock worth studying right now? What the numbers show: Krystal Biotech, Inc.'s earnings have grown faster than its share price. Earnings per share grew +128.0% in a year while the price moved +51.7%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.